← Leaderboards
Sumita Bhaduri-McIntosh
Yale University
$6,616,001
Attributed
$8,125,644
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,125,644 · 6
By mechanism
R01$4,345,677 · 3
U01$3,019,287 · 1
K08$535,680 · 1
R41$225,000 · 1
Top collaborators
- Michael T Mcintosh5 shared
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaB-LymphocytesCellsHuman Herpesvirus 4Malignant NeoplasmsCancer CellPredispositionMediatingProteinsVirusGenesGenome-WideTranscriptHerpesviridaeViralPathway InteractionsTranscription FactorLinkCell LineInfected B CellAcquired Immunodeficiency SyndromeLyticNon-Hodgkin&AposCessation Of Life
Grant awards (20)
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV$676,145
U01 · FY2025 · CA · contact PI
Understanding viral mechanisms to inform oncolytic therapies for EBV-associated lymphomas in PLWH$601,309
R01 · FY2025 · DE · contact PI
Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors$593,500
R01 · FY2025 · DE · contact PI
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV$750,686
U01 · FY2024 · CA · contact PI
Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors$599,564
R01 · FY2024 · DE · contact PI
PROTAC-based direct and oncolytic killing of EBV+ DLBCLs through synthetic lethality$152,500
U01 · FY2024 · CA · contact PI
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV$750,686
U01 · FY2023 · CA · contact PI
Exposing synthetic lethal vulnerabilities in EBV-positive AIDS-NHL through novel replication dependency factors$611,800
R01 · FY2023 · DE · contact PI
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV$689,270
U01 · FY2022 · CA · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$381,250
R01 · FY2018 · AI · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$327,875
R01 · FY2017 · AI · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$52,871
R01 · FY2017 · AI · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$392,571
R01 · FY2016 · AI · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$392,571
R01 · FY2015 · AI · contact PI
sxRNA-based Antiviral Approach targeting Epstein-Barr virus$225,000
R41 · FY2015 · AI · contact PI
Host determinants of Epstein-Barr virus lytic cycle activation$392,366
R01 · FY2014 · AI · contact PI
Early cellular immune responses to EBV$136,620
K08 · FY2008 · AI · contact PI
Early cellular immune responses to EBV$136,620
K08 · FY2007 · AI · contact PI
Early cellular immune responses to EBV$136,620
K08 · FY2006 · AI · contact PI
Early cellular immune responses to EBV$125,820
K08 · FY2005 · AI